The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several new combination therapies have been approved for the treatment of COPD, further increasing the competition. Although these new therapies perform well on a variety of clinical end points, most offer only incremental improvements, and none have yet demonstrated a statistically significant decrease in all-cause mortality. Owing to the high level of unmet need in COPD, significant clinical and commercial opportunity remains for therapies that can provide a decrease in all-cause mortality, number of exacerbations, or improvement on several clinically important end points, including FEV1 and frequency of exacerbations, compared with current standards of care.

Table of contents

  • Detailed, Expanded Analysis
    • Treatment Drivers and Goals
      • Overview
      • Treatment Drivers and Goals
        • Methodology
        • Physician Weighting of Clinical and Non-Clinical Attributes
        • Rationale for Treatment Drivers and Goals Selection
      • Physician Rating of Treatment Drivers and Goals in Chronic Obstructive Pulmonary Disease
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
      • Stated Versus Derived Importance of Treatment Drivers and Goals
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
      • Physician Rating of Unmet Need in Chronic Obstructive Pulmonary Disease
        • Efficacy
        • Convenience of Administration
        • Non-Clinical Factors
      • Unmet Need in Chronic Obstructive Pulmonary Disease and Related Indications
    • Opportunity Analysis
      • Areas of Opportunity in the Chronic Obstructive Pulmonary DiseasMarket and Emerging Therapy Insights
        • Opportunity: A Combination Therapy That Improves Overall Survival
        • Opportunity: A Biologic or Small-Molecule Therapy That Reduces Inflammation and Exacerbations
        • Opportunity: Therapies That Outperform Current Drugs on FEV1 and TDI Focal Score
        • Opportunity: Therapies That Are More Convenient and Have a Decreased Dosing Burden
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
      • Attribute Importance and Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Scenario 1
        • Scenario 2

Author(s): Kristine Mackin, PhD

Kristine Mackin, is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD. She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


Related Reports

Chronic Obstructive Pulmonary Disease | Current Treatment | Detailed, Expanded Analysis (US): Treatment Algorithms: Claims Data Analysis

Long-acting beta2agonist (LABA)/long-acting muscarinic antagonist (LAMA) fixed-dos...

View Details

Chronic Obstructive Pulmonary Disease | Access & Reimbursement | Detailed, Expanded Analysis (US) Inhaled COPD Therapies

Medicare beneficiaries with chronic obstructive pulmonary disease (COPD) have access to more than a dozen long-acting bronchodilator inh...

View Details

Chronic Obstructive Pulmonary Disease | Unmet Need | Detailed, Expanded Analysis: Moderate to Severe (US/EU)

The chronic obstructive pulmonary disease (COPD) therapy market continues to suffer from the absence of any agents that can reverse dise...

View Details

Chronic Obstructive Pulmonary Disease | Landscape & Forecast | Disease Landscape & Forecast

Thechronic obstructive pulmonary disease(COPD) market is continuing its gradual shift away from long-acting beta2 agonist/inhaled cortic...

View Details